Page last updated: 2024-12-06

sesamodil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sesamodil is a synthetic analog of the natural compound sesamolin, which is found in sesame seeds. It is a potent antioxidant and has been shown to have neuroprotective effects. Sesamodil is currently being studied for its potential therapeutic applications in conditions such as Alzheimer's disease and Parkinson's disease. Research has shown that it has the ability to inhibit the formation of amyloid plaques and to protect neurons from oxidative stress.'

sesamodil: structure given in first source; RN given refers to fumarate [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65929
CHEMBL ID57684
SCHEMBL ID80715
MeSH IDM0177285

Synonyms (18)

Synonym
116476-13-2
semotiadil
sesamodil
(+-(r)-2-(5-methoxy-2-(3-(methyl(2-(3,4-(methylenedioxy)phenoxy)ethyl)amino)propoxy)phenyl)-4-methyl-2h-1,4-benzothiazin-3(4h)-one
semotiadilum [inn-latin]
semotiadil [inn]
CHEMBL57684
(2r)-2-[2-[3-[2-(1,3-benzodioxol-5-yloxy)ethyl-methylamino]propoxy]-5-methoxyphenyl]-4-methyl-1,4-benzothiazin-3-one
semotiadilum
unii-dgn08qz30g
dgn08qz30g ,
semotiadil [mi]
SCHEMBL80715
(r)-2-(2-(3-((2-(benzo[d][1,3]dioxol-5-yloxy)ethyl)(methyl)amino)propoxy)-5-methoxyphenyl)-4-methyl-2h-benzo[b][1,4]thiazin-3(4h)-one
116476-13-2 (free base)
Q7456017
DTXSID30869602
AKOS040749485

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" These results indicate that SD-3211 is an antihypertensive agent with long-lasting action and little effect on heart rate and atrioventricular conduction and, when administered alone or in combination with propranolol, may be useful in the treatment of hypertension."( SD-3211, a novel benzothiazine calcium antagonist, alone and in combination with a beta-adrenoceptor antagonist, produces antihypertensive effects without affecting heart rate and atrioventricular conduction in conscious renal hypertensive dogs.
Kageyama, M; Miyawaki, N; Nishimura, K; Takada, T; Yamauchi, H, 1991
)
0.28
"Semotiadil fumarate, a novel benzothiazine calcium antagonist, was given alone or in combination with either enalapril or trichlormethiazide to conscious, spontaneously hypertensive, rats daily for 2 weeks."( Antihypertensive effects of a novel calcium antagonist, semotiadil fumarate (SD-3211), alone and in combination with enalapril or trichlormethiazide in spontaneously hypertensive rats.
Akashi, S; Ichikawa, M; Koida, M; Machidera, Y; Manno, K; Nakamuta, H; Ohtsuji, T; Wanaka, M, 1994
)
0.29

Dosage Studied

ExcerptRelevanceReference
" These results indicate that combined daily dosing of semotiadil, especially with enalapril, each at relatively low doses may be able to control hypertension in a continuous manner."( Antihypertensive effects of a novel calcium antagonist, semotiadil fumarate (SD-3211), alone and in combination with enalapril or trichlormethiazide in spontaneously hypertensive rats.
Akashi, S; Ichikawa, M; Koida, M; Machidera, Y; Manno, K; Nakamuta, H; Ohtsuji, T; Wanaka, M, 1994
)
0.29
"3% of the dosed radioactivity was excreted into the bile."( Biliary metabolites of semotiadil fumarate in the rat.
Hakusui, H; Katoh, K; Nakaoka, M, 1995
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID80317Inhibitory concentration required to suppress the rate of contraction of guinea pig right atria1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and Ca2+ antagonistic activity of 2-[2-[(aminoalkyl)oxy]-5-methoxyphenyl]-3,4-dihydro-4-methyl-3-oxo-2H- 1,4-benzothiazines.
AID232671Selectivity ratio of IC50 for [Ca2+] antagonistic activity in aorta / IC50 for suppressive effect on rate of contraction1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and Ca2+ antagonistic activity of 2-[2-[(aminoalkyl)oxy]-5-methoxyphenyl]-3,4-dihydro-4-methyl-3-oxo-2H- 1,4-benzothiazines.
AID80316Inhibitory concentration required to suppress the contractile force of guinea pig right atria1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and Ca2+ antagonistic activity of 2-[2-[(aminoalkyl)oxy]-5-methoxyphenyl]-3,4-dihydro-4-methyl-3-oxo-2H- 1,4-benzothiazines.
AID232670Selectivity ratio of IC50 for [Ca2+] antagonistic activity in aorta / IC50 for suppressive effect on contractile force1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and Ca2+ antagonistic activity of 2-[2-[(aminoalkyl)oxy]-5-methoxyphenyl]-3,4-dihydro-4-methyl-3-oxo-2H- 1,4-benzothiazines.
AID80458Inhibitory concentration required to block Ca+2 induced contraction of K+ depolarized guinea pig taenia cecum1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and Ca2+ antagonistic activity of 2-[2-[(aminoalkyl)oxy]-5-methoxyphenyl]-3,4-dihydro-4-methyl-3-oxo-2H- 1,4-benzothiazines.
AID80725Inhibitory concentration required to block Ca+2 induced contraction of K+ depolarized guinea pig aorta1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and Ca2+ antagonistic activity of 2-[2-[(aminoalkyl)oxy]-5-methoxyphenyl]-3,4-dihydro-4-methyl-3-oxo-2H- 1,4-benzothiazines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (51)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's45 (88.24)18.2507
2000's6 (11.76)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.18 (24.57)
Research Supply Index3.97 (2.92)
Research Growth Index4.15 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.92%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other51 (98.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]